Alvotech Eyes Canada Humira Launch As Celltrion Also Bags High-Strength Approval
Celltrion’s Yuflyma And Alvotech/JAMP’s Simlandi Approved By Health Canada
Executive Summary
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
You may also be interested in...
Canada Sees Face-Off Over Higher-Strength Adalimumab
Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.
Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.
Canada’s Jamp Creates Dedicated Biosimilars Division
Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.